ConductScience.org, home

Paper31324697

Efavirenz Metabolism: Influence of Polymorphic CYP2B6 Variants and Stereochemistry.

Wang PF and 2 others. Drug Metab Dispos, 2019. Cited by 50 papers, by iCite.

Cite this record

ConductScience Library. Efavirenz Metabolism: Influence of Polymorphic CYP2B6 Variants and Stereochemistry. Papers, record 31324697. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31324697

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Efavirenz Metabolism: Influence of Polymorphic CYP2B6 Variants and Stereochemistry.
PubMed
Journal
Drug Metab Dispos
PubMed
Year
2019
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review
PubMed
Citations, by iCite
50
iCite
Relative citation ratio, by iCite
3.19
iCite
Revised in PubMed
2025-02-12
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wang PFPan-Fen
2Neiner AAlicia
3Kharasch EDEvan D

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
BenzoxazinesMajor topic
Cytochrome P-450 CYP2B6Major topic
HIV InfectionsMajor topic
Reverse Transcriptase InhibitorsMajor topic
Alkynes
Animals
Cell Line
Cyclopropanes
Humans
Insecta
Polymorphism, Single Nucleotide
Recombinant Proteins
Stereoisomerism

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
R01 DA014211NIDA NIH HHSUnited StatesR01DA014211PubMed and NIH

Source NIH RePORTER

Download CSV of grants

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Erratum in31562132Correction to "Efavirenz Metabolism: Influence of Polymorphic CYP2B6 Variants and Stereochemistry".https://conductscience.org/library/papers/31562132

Source PubMed

Download CSV of comments and corrections

References72

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
118294336Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers.Br J Clin Pharmacol2008https://conductscience.org/library/papers/18294336PubMed
218645035Multiple substrate binding by cytochrome P450 3A4: estimation of the number of bound substrate molecules.Drug Metab Dispos2008https://conductscience.org/library/papers/18645035PubMed
324497997Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes.PLoS One2014https://conductscience.org/library/papers/24497997PubMed
418621926Investigation of the mechanisms underlying the differential effects of the K262R mutation of P450 2B6 on catalytic activity.Mol Pharmacol2008https://conductscience.org/library/papers/18621926PubMed
519239339Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans.J Infect Dis2009https://conductscience.org/library/papers/19239339PubMed
621821736Q172H replacement overcomes effects on the metabolism of cyclophosphamide and efavirenz caused by CYP2B6 variant with Arg262.Drug Metab Dispos2011https://conductscience.org/library/papers/21821736PubMed
730085944Stereoselective Ketamine Metabolism by Genetic Variants of Cytochrome P450 CYP2B6 and Cytochrome P450 Oxidoreductase.Anesthesiology2018https://conductscience.org/library/papers/30085944PubMed
817259447Enantiomeric metabolic interactions and stereoselective human methadone metabolism.J Pharmacol Exp Ther2007https://conductscience.org/library/papers/17259447PubMed
916392090Efavirenz and CYP2B6 polymorphism: implications for drug toxicity and resistance.Clin Infect Dis2006https://conductscience.org/library/papers/16392090PubMed
1027600044Inhibition of Cytochrome P450 2B6 Activity by Voriconazole Profiled Using Efavirenz Disposition in Healthy Volunteers.Antimicrob Agents Chemother2016https://conductscience.org/library/papers/27600044PubMed
1123166317Compartmentalization and antiviral effect of efavirenz metabolites in blood plasma, seminal plasma, and cerebrospinal fluid.Drug Metab Dispos2013https://conductscience.org/library/papers/23166317PubMed
129241656Examination of purported probes of human CYP2B6.Pharmacogenetics1997https://conductscience.org/library/papers/9241656PubMed
1310681367In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model.Drug Metab Dispos2000https://conductscience.org/library/papers/10681367PubMed
1426655325CYP2B6*6 and CYP2B6*18 Predict Long-Term Efavirenz Exposure Measured in Hair Samples in HIV-Positive South African Women.AIDS Res Hum Retroviruses2016https://conductscience.org/library/papers/26655325PubMed
1525611810Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.Br J Clin Pharmacol2015https://conductscience.org/library/papers/25611810PubMed
169862748Three-dimensional quantitative structure activity relationship analyses of substrates for CYP2B6.J Pharmacol Exp Ther1999https://conductscience.org/library/papers/9862748PubMed
1726686The effect of pH on the cooperative behavior of aspartate transcarbamylase from Escherichia coli.J Biol Chem1978https://conductscience.org/library/papers/26686PubMed
1828145050Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms : a substudy of the ANRS ALIZE trial.HIV Med2017https://conductscience.org/library/papers/28145050PubMed
1916611850Metabolism of efavirenz and 8-hydroxyefavirenz by P450 2B6 leads to inactivation by two distinct mechanisms.J Pharmacol Exp Ther2006https://conductscience.org/library/papers/16611850PubMed
2021659470
Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase complex.
J Pharmacol Exp Ther2011https://conductscience.org/library/papers/21659470PubMed

See all 72 referencesDownload CSV of references

Cited by35

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 50 citations.

PMIDTitleJournalYearIn PapersSource
42296571Pharmacogenomics of antibacterial and antiviral therapies: Clinical actionability, evidence gaps, and future directions.Pharmacol Rev2026https://conductscience.org/library/papers/42296571PubMed
42196482Efavirenz-Altered Gut-Microbiota, Tph1, and Systemic 5-HT Levels: Could They Affect Depression Mechanisms in Mice?Int J Mol Sci2026https://conductscience.org/library/papers/42196482PubMed
42027046Stereoselective Biotransformation: Transfer of Learning to Advance Drug Metabolism and Biocatalysis.Angew Chem Int Ed Engl2026https://conductscience.org/library/papers/42027046PubMed
41948624Strengthening Pharmacogenomics Implementation in Africa: Challenges and Opportunities - A Narrative Review.Health Sci Rep2026https://conductscience.org/library/papers/41948624PubMed
41805453Changes in Metabolic Parameters After Switching From Efavirenz to Dolutegravir-Based Regimen: A Cohort Study in Thai People Living With HIV.J Int Assoc Provid AIDS Care2026https://conductscience.org/library/papers/41805453PubMed
41674639Distinct biochemical phenotypes of HIV exposed infants driven by antiviral medication.medRxiv2026https://conductscience.org/library/papers/41674639PubMed
41149818Pharmacogenomics in Orofacial Clefts Care: Insights from Whole-Genome Sequencing of Case-Parents Trios.J Pers Med2025https://conductscience.org/library/papers/41149818PubMed
41061300Applicability domain-expansion studies for machine learning models reveal new inhibitors of CYP2B6.Drug Metab Dispos2025https://conductscience.org/library/papers/41061300PubMed
40968422Application of Physiologically Based Pharmacokinetic Modeling in the Research of Anti-HIV Drugs.Curr Drug Metab2025https://conductscience.org/library/papers/40968422PubMed
40851704Population Pharmacokinetic-Pharmacogenetic (PopPK-PGx) Model of Efavirenz in HIV-1-Infected Patients.Cureus2025https://conductscience.org/library/papers/40851704PubMed
40110576Precision medication based on the evaluation of drug metabolizing enzyme and transporter functions.Precis Clin Med2025https://conductscience.org/library/papers/40110576PubMed
39768746High Prevalence of Severe Depression in Mexican Patients Diagnosed with HIV Treated with Efavirenz and Atazanavir: Clinical Follow-Up at Four Weeks and Analysis of TPH2 SNPs.J Clin Med2024https://conductscience.org/library/papers/39768746PubMed
39735593Overweight and Obesity Among People Living With HIV on Dolutegravir- and Efavirenz-Based Therapies: A Comparative Cross-Sectional Study.AIDS Res Treat2024https://conductscience.org/library/papers/39735593PubMed
39371070Liver Damage During Treatment with Reverse-Transcriptase Inhibitors in HIV Patients.Curr Health Sci J2024https://conductscience.org/library/papers/39371070PubMed
39339201PBPK Modeling of Lamotrigine and Efavirenz during Pregnancy: Implications for Personalized Dosing and Drug-Drug Interaction Management.Pharmaceutics2024https://conductscience.org/library/papers/39339201PubMed
39066420Safety and Efficacy of Antiviral Drugs and Vaccines in Pregnant Women: Insights from Physiologically Based Pharmacokinetic Modeling and Integration of Viral Infection Dynamics.Vaccines (Basel)2024https://conductscience.org/library/papers/39066420PubMed
38931468Oral Administration of Efavirenz Dysregulates the Tph2 Gene in Brain Serotonergic Areas and Alters Weight and Mood in Mice.Pharmaceuticals (Basel)2024https://conductscience.org/library/papers/38931468PubMed
383969197,8-Dihydroxy Efavirenz Is Not as Effective in CYP46A1 Activation In Vivo as Efavirenz or Its 8,14-Dihydroxy Metabolite.Int J Mol Sci2024https://conductscience.org/library/papers/38396919PubMed
38332525Body weight and blood pressure changes on dolutegravir-, efavirenz- or atazanavir-based antiretroviral therapy in Zimbabwe: a longitudinal study.J Int AIDS Soc2024https://conductscience.org/library/papers/38332525PubMed
38135504Natural Products Inhibition of Cytochrome P450 2B6 Activity and Methadone Metabolism.Drug Metab Dispos2024https://conductscience.org/library/papers/38135504PubMed

See all 35 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
CYP2B61555PubTator's text mininghttps://conductscience.org/library/genes/1555

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/31324697

GET https://conductscience.org/api/papers/v1/31324697/references?page=2